-+ 0.00%
-+ 0.00%
-+ 0.00%

Wedbush Maintains Outperform on Beam Therapeutics, Raises Price Target to $65

Benzinga·02/25/2026 13:24:53
Listen to the news
Wedbush analyst David Nierengarten maintains Beam Therapeutics (NASDAQ:BEAM) with a Outperform and raises the price target from $57 to $65.